MedTrace Logo

A Single Dose Study to Investigate the Pharmacokinetics of MK-0941 in Participants With Renal Insufficiency (MK-0941-015-02)

NCT00830791 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2015-02-26

Study results available
· View outcomes & findings →

Summary

This study will assess the pharmacokinetics of MK-0941 in participants with varying degrees of renal insufficiency.

Conditions

Interventions

DRUG

MK-0941 20 mg

Two 10-mg tablets of MK-0941 administered as a single oral dose.

DRUG

MK-0941 5 mg

MK-0941 administered as one single 5-mg tablet.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-09-30
Completion
2009-09-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830791 on ClinicalTrials.gov